iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.8300
-0.0192 (-2.26%)
At close: May 8, 2025, 4:00 PM
0.8300
0.00 (0.00%)
Pre-market: May 9, 2025, 4:16 AM EDT
iBio, Inc. Revenue
iBio, Inc. had revenue of $375.00K in the twelve months ending March 31, 2025, up 650.00% year-over-year. In the fiscal year ending June 30, 2024, iBio, Inc. had annual revenue of $225.00K.
Revenue (ttm)
$375.00K
Revenue Growth
+650.00%
P/S Ratio
20.02
Revenue / Employee
$23,438
Employees
16
Market Cap
8.20M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
IBIO News
- 3 days ago - iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - GlobeNewsWire
- 6 days ago - iBio Reports Fiscal Third Quarter 2025 Financial Results - GlobeNewsWire
- 9 days ago - iBio Raises $6.2 Million Through Warrant Inducement Transaction - GlobeNewsWire
- 16 days ago - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - GlobeNewsWire
- 4 weeks ago - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - GlobeNewsWire
- 2 months ago - iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewsWire
- 3 months ago - iBio Reports Fiscal Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio - GlobeNewsWire